Breakthrough trial tests promising new combo against rare, deadly organ disease
NCT ID NCT07388602
Summary
This study is testing whether adding a new drug called SCTC21C to a standard three-drug combination works better and is safe for people newly diagnosed with light-chain amyloidosis, a rare disease where abnormal proteins damage organs. It will involve 90 participants who will receive either the new four-drug combination or the standard three-drug combination. The main goal is to see if the new combination leads to a better and longer-lasting reduction of the harmful proteins in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.